Na Rong

1.Innovative Asset Evaluation & Licensing Strategy

• Co-lead out-licensing strategy for high-potential assets by analyzing epidemiology, competitive landscape (benchmarks, MOA, SOC), and unmet needs to prioritize partnerships.
• Conducted due diligence on 10+ therapeutic targets/technologies, authored strategic reports (clinical/preclinical data, market potential, risk analysis), and prepared investor/partner-ready materials (VDR).
• Collaborated with R&D to design differentiated preclinical/clinical studies, including head-to-head benchmarking against key competitors.

2.In-Licensing Readiness & Market Analysis

• Evaluated in-licensing candidates by assessing technical novelty (MoA validation), preclinical/clinical data robustness, development timelines, and team credibility.
• Modeled market potential for innovative assets by analyzing target population, global/China competition, and commercial/clinical regulatory pathways.

3.Strategic Alliance Execution

• Spearheaded end-to-end alliance management for soft mist platform, driving one 505b2 asset from Project Initiation into Phase III prep through cross-functional alignment (R&D, RA, clinical teams).
• Prepare materials for project approval for 2 early-stage 505b2 programs, by defining comprehensive competitive landscape analysis, clinical and regulatory pathways, regulatory risk assessments, commercialization timelines, and market size projection.

1. Project Initiation & Planning:

• Authored the project proposal, including feasibility analysis, budget allocation, and milestone-driven timelines.
• Spearheaded hypothesis-driven studies to evaluate exosome cargo (miRNA, proteins) for targeted drug delivery applications.

2.Experimental Design & Execution:

• Led a 3-member team in the end-to-end development of an exosome-based therapeutic program, from project initiation to preclinical validation.
• Designed and optimized protocols for exosome isolation (e.g., ultracentrifugation, SEC), characterization (NTA, TEM, Western blot), and functional analysis in in vitro models).